-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, EXTUhU94GVsQUFAP1kHqJVCmzgX7G7JAnbn+AFwY+dCJgj9BTTUgQr/CWgZxMp+h vMa5iWgdyfQhZAaAHS2PCw== 0000950135-04-002872.txt : 20040601 0000950135-04-002872.hdr.sgml : 20040601 20040601111036 ACCESSION NUMBER: 0000950135-04-002872 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20040528 ITEM INFORMATION: Other events FILED AS OF DATE: 20040601 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TRANSKARYOTIC THERAPIES INC CENTRAL INDEX KEY: 0000885259 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 043027191 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-21481 FILM NUMBER: 04840148 BUSINESS ADDRESS: STREET 1: 195 ALBANY ST CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 6173490200 8-K 1 b50759tke8vk.htm TRANSKARYOTIC THERAPIES, INC. TRANSKARYOTIC THERAPIES, INC.
Table of Contents

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported):   May 28, 2004

Transkaryotic Therapies, Inc.

(Exact name of registrant as specified in charter)
         
Delaware   000-21481   04-3027191
 
(State or other juris-
diction of incorporation) 		  (Commission
File Number) 		  (IRS Employer
Identification No.)
     
700 Main Street, Cambridge, Massachusetts   02139
 
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code:   (617) 349-0200

(Former name or former address, if changed since last report)

 

TABLE OF CONTENTS

Item 5. Other Events and Required FD Disclosure.
SIGNATURE

Table of Contents

Item 5. Other Events and Required FD Disclosure.

     On May 4, 2004, Transkaryotic Therapies, Inc. (“TKT” or the “Company”) sold $90 million principal amount of 1.25% senior convertible notes due 2011 (the “Notes”). In connection with the sale of the Notes, the Company granted to the underwriters of the offering an overallotment option to purchase an additional $10 million principal amount of the Notes within 30 days of the offering pursuant to an underwriting agreement (the “Underwriting Agreement”) entered into with JP Morgan Securities Inc., as representative of the several underwriters, dated April 28, 2004. On May 28, 2004, the Company and JP Morgan Securities Inc. amended the underwriting agreement to extend the exercise period for the underwriters’ overallotment option from 30 days after the offering to 45 days after the offering.

 

Table of Contents

SIGNATURE

     Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

         
Date:  June 1, 2004   TRANSKARYOTIC THERAPIES, INC.
 
        
  By:   /s/Gregory D. Perry
     
 
      Gregory D. Perry
      Vice President and Chief Financial Officer

 

-----END PRIVACY-ENHANCED MESSAGE-----